General Information


We are a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, known as hemoglobinopathies. Our pipeline is built on the differentiated therapeutic potential of our initial product candidate, IMR-687, which is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease, or SCD, and b-thalassemia. IMR-687 is a highly selective, potent small molecule inhibitor of phosphodiesterase-9, or PDE9, that has a multimodal mechanism of action that acts primarily on red blood cells, or RBCs, and has the potential to act on white blood cells, or WBCs, adhesion mediators and other cell types that are implicated in these disorders.

Employees: 20
Founded: 2016
Contact Information
Address 116 Huntington Avenue, 6th Floor, Boston, MA 02116, US
Phone Number (617) 206-2020
Web Address
View Prospectus: IMARA Inc.
Financial Information
Market Cap $265.2mil
Revenues $0 mil (last 12 months)
Net Income $-23.5 mil (last 12 months)
IPO Profile
Symbol IMRA
Exchange NASDAQ
Shares (millions): 4.7
Price range $16.00 - $16.00
Est. $ Volume $75.2 mil
Manager / Joint Managers Morgan Stanley/ Citigroup/ SVB Leerink
CO-Managers -
Expected To Trade: 3/12/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change